PD-L 1 expression in nonclear-cell renal cell carcinoma

update. Eur Urol 2011; 60: 304–319. 18. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Testicular Cancer 2012. NCCN. http://www.nccn.org (30 June 2013, date last accessed). 19. Oliver RTD, Mead GM, Rustin GJS et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC30982 Study (ISRCTN27163214). J Clin Oncol 2011; 29: 957–962. 20. Powles T, Robinson D, Shamash J et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008; 19: 443–447. 21. Soper MS, Hastings JR, Cosmatos HA et al. Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma; clinical outcomes and prognostic factors for relapse in a large US cohort. Am J Clin Oncol 2014; 37: 356–359. 22. Kamba T, Kamoto T, Okubo K et al. Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol 2010; 17: 980–988.

[1]  T. Choueiri,et al.  Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. , 2014 .

[2]  J. Cheville,et al.  The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters , 2013, The American journal of surgical pathology.

[3]  J. Bellmunt,et al.  Targeted therapies and the treatment of non-clear cell renal cell carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  T. Choueiri,et al.  Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma , 2013, Cancer journal.

[5]  T. Powles,et al.  Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). , 2013 .

[6]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[7]  T. Choueiri,et al.  Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. , 2011, Hematology/oncology clinics of North America.

[8]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[9]  S. Boorjian,et al.  T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. , 2009, Urology.

[10]  P. Camparo,et al.  Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  T. Choueiri,et al.  Non-clear cell renal cancer: features and medical management. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  R. Figlin,et al.  Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies , 2009, Medical oncology.

[13]  J. Allison,et al.  Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.

[14]  J. Cheville,et al.  PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[15]  R. Thompson,et al.  Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy , 2007, Clinical Cancer Research.

[16]  J. Cheville,et al.  Mononuclear cell infiltration in clear‐cell renal cell carcinoma independently predicts patient survival , 2006, Cancer.

[17]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[18]  F. McGovern,et al.  Renal-cell carcinoma. , 2005, The New England journal of medicine.

[19]  R. Figlin,et al.  Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. , 2003, The Urologic clinics of North America.

[20]  R. Motzer,et al.  Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Figlin.  Renal cell carcinoma: management of advanced disease. , 1999, The Journal of urology.

[23]  T. Choueiri,et al.  Precision medicine for metastatic renal cell carcinoma. , 2014, Urologic oncology.

[24]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[25]  Gudrun Schleiermacher,et al.  Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. , 2011, The Journal of urology.

[26]  S. Culine,et al.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Gordon.  Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma , 2009 .

[28]  J. Cheville,et al.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.